» Articles » PMID: 34572779

Metallothionein 2A Expression in Cancer-Associated Fibroblasts and Cancer Cells Promotes Esophageal Squamous Cell Carcinoma Progression

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Sep 28
PMID 34572779
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Esophageal cancer has the sixth highest mortality rate worldwide. Cancer-associated fibroblasts (CAFs) are involved in the progression of various cancers. Previously, we demonstrated an association between high expression of the CAF marker, fibroblast activation protein, and poor prognosis of esophageal squamous cell carcinoma (ESCC). We also established CAF-like cells by indirect co-culture of bone marrow-derived mesenchymal stem cells with ESCC cell lines and found metallothionein 2A (MT2A) to be highly expressed in them. Here, to explore the function of MT2A in CAFs, we silenced in the CAF-like cells and ESCC cell lines using small interfering RNA. knockdown in the CAF-like cells suppressed expression and secretion of insulin-like growth factor binding protein 2 (IGFBP2); recombinant IGFBP2 promoted migration and invasiveness of ESCC cells via NFκB, Akt, and Erk signaling pathways. Furthermore, knockdown in the ESCC cell lines inhibited their growth, migration, and invasiveness. Immunohistochemistry demonstrated that high MT2A expression in the cancer stroma and cancer nest of ESCC tissues correlated with poor prognosis of ESCC patients. Hence, we report that MT2A in CAFs and cancer cells contributes to ESCC progression. MT2A and IGFBP2 are potential novel therapeutic targets in ESCC.

Citing Articles

AREG Upregulation in Cancer Cells via Direct Interaction with Cancer-Associated Fibroblasts Promotes Esophageal Squamous Cell Carcinoma Progression Through EGFR-Erk/p38 MAPK Signaling.

Nakanishi T, Koma Y, Miyako S, Torigoe R, Yokoo H, Omori M Cells. 2024; 13(20.

PMID: 39451251 PMC: 11506648. DOI: 10.3390/cells13201733.


Comprehensive analysis of hub genes associated with cisplatin-resistance in ovarian cancer and screening of therapeutic drugs through bioinformatics and experimental validation.

Zhu Y, Chen X, Tang R, Li G, Yang J, Hong S J Ovarian Res. 2024; 17(1):142.

PMID: 38987777 PMC: 11234624. DOI: 10.1186/s13048-024-01461-w.


Elucidating Hedgehog pathway's role in HNSCC progression: insights from a 6-gene signature.

Yang Y, Yang C, Yang Q, Lu S, Liu B, Li D Sci Rep. 2024; 14(1):4686.

PMID: 38409358 PMC: 10897175. DOI: 10.1038/s41598-024-54937-6.


Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets.

Chen B, Yu P, Chan W, Xie F, Zhang Y, Liang L Signal Transduct Target Ther. 2024; 9(1):6.

PMID: 38169461 PMC: 10761908. DOI: 10.1038/s41392-023-01679-y.


Influence of C Nanofilm on the Expression of Selected Markers of Mesenchymal-Epithelial Transition in Hepatocellular Carcinoma.

Sosnowska M, Kutwin M, Zawadzka K, Pruchniewski M, Strojny B, Bujalska Z Cancers (Basel). 2023; 15(23).

PMID: 38067256 PMC: 10705132. DOI: 10.3390/cancers15235553.


References
1.
Tsuyada A, Chow A, Wu J, Somlo G, Chu P, Loera S . CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 2012; 72(11):2768-79. PMC: 3367125. DOI: 10.1158/0008-5472.CAN-11-3567. View

2.
Tiasto V, Mikhailova V, Gulaia V, Vikhareva V, Zorin B, Kalitnik A . Esophageal cancer research today and tomorrow: Lessons from algae and other perspectives. AIMS Genet. 2019; 5(1):75-90. PMC: 6690251. DOI: 10.3934/genet.2018.1.75. View

3.
Li T, Forbes M, Fuller G, Li J, Yang X, Zhang W . IGFBP2: integrative hub of developmental and oncogenic signaling network. Oncogene. 2020; 39(11):2243-2257. PMC: 7347283. DOI: 10.1038/s41388-020-1154-2. View

4.
Wang Y, Zhu L, Xia W, Wang F . Anatomy of lymphatic drainage of the esophagus and lymph node metastasis of thoracic esophageal cancer. Cancer Manag Res. 2018; 10:6295-6303. PMC: 6267772. DOI: 10.2147/CMAR.S182436. View

5.
Clemmons D . Insulinlike growth factor binding proteins. Trends Endocrinol Metab. 1990; 1(8):412-7. DOI: 10.1016/1043-2760(90)90102-9. View